Please use this identifier to cite or link to this item:
Title: Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Authors: Alonso-Álvarez, Sara
Magnano, Laura
Alcoceba, Miguel
Andrade-Campos, Marcio
Espinosa-Lara, Natalia
Rodríguez, Guillermo
Mercadal, Santiago
Carro, Itziar
Sancho, Juan M
Moreno, Miriam
Salar, Antonio
García-Pallarols, Francesc
Arranz, Reyes
Cannata, Jimena
Terol, María José
Teruel, Ana I
Rodríguez, Antonia
Jiménez-Ubieto, Ana
González de Villambrosia, Sonia
Bello, José L
López, Lourdes
Monsalvo, Silvia
Novelli, Silvana
de Cabo, Erik
Infante, María S
Pardal, Emilia
García-Álvarez, María
Delgado, Julio
González, Marcos
Martín, Alejandro
López-Guillermo, Armando
Caballero, María D
Keywords: cumulative incidence;follicular lymphoma;transformation
metadata.dc.subject.mesh: Adolescent
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Cell Transformation, Neoplastic
Disease Progression
Lymphoma, Follicular
Middle Aged
Neoplasm Staging
Retrospective Studies
Risk Assessment
Survival Analysis
Young Adult
Issue Date: 7-Aug-2017
Abstract: The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1-3A, were, (i) the cumulative incidence of HT (CI-HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow-up of 6·2 years, 106 patients developed HT. Ten-year CI-HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2·5 years. High-risk FL International Prognostic Index [Hazard ratio (HR) 2·6, 95% confidence interval (CI): 1·5-4·5] and non-response to first-line therapy (HR 2·9, 95% CI: 1·3-6·8) were associated with HT. Seventy out of the 106 patients died (5-year SFT, 26%). Response to HT first-line therapy (HR 5·3, 95% CI: 2·4-12·0), autologous stem cell transplantation (HR 3·9, 95% CI: 1·5-10·1), and revised International Prognostic Index (HR 2·2, 95% CI: 1·1-4·2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.
metadata.dc.identifier.doi: 10.1111/bjh.14831
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.